{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:32:30Z","timestamp":1789414350898,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>M\u00fcllerian adenosarcoma (MA) is a rare low-grade malignant tumor. It is characterized by benign glandular epithelium and malignant sarcomatous stromal components. This tumor commonly arises in the uterine corpus. Primary ovarian MA is uncommon and typically presents as a unilateral lesion (FIGO stages I-III). However, bilateral ovarian involvement coupled with extensive metastasis in ovarian adenosarcoma has not been previously reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This article reports a rare case of bilateral primary ovarian adenosarcoma with extensive metastasis and lymphovascular invasion (LVI). Histopathological examination revealed a biphasic tumor composed of proliferative glands and stroma. The glandular epithelium was separated by abundant stromal components, forming a lobulated architecture resembling a breast phyllodes tumor. The glandular epithelial cells exhibited a single-layered columnar morphology with bland cytological features. In contrast, the stromal cells displayed a spindle-shaped morphology, arranged densely around spiral artery-like vessels. These stromal cells showed mild atypia with visible mitotic figures. Notably, periglandular stromal condensation formed a characteristic \u201ccuff-like\u201d pattern. Extensive metastases were identified in multiple sites: the subumbilical region, intestinal tract, omentum, and distal segment of the right ureter. Significantly, tumor emboli were detected within vascular channels beneath the rectal serosa. Molecular analysis revealed novel findings. Next-generation sequencing (NGS) identified a GNAQ mutation, previously unreported in this tumor type. Additionally, immunohistochemical (IHC) analysis confirmed positive PD-L1 expression. Finally, the patient received a comprehensive treatment regimen comprising radiotherapy, chemotherapy, and immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      We describe a unique case of ovarian adenosarcoma presenting with bilateral ovarian involvement, manifesting at the more advanced stage IIIC, notably in the absence of sarcomatous overgrowth (SO). Moreover, we report for the first time the presence of LVI and the\n                      <jats:italic>GNAQ<\/jats:italic>\n                      missense variant in ovarian adenosarcoma.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1657939","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:27Z","timestamp":1764739227000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: A rare case of bilateral primary M\u00fcllerian adenosarcoma of the ovary with Uncommon extensive metastasis and GNAQ mutation"],"prefix":"10.3389","volume":"15","author":[{"given":"Shuying","family":"Ai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197410)34:4<1138::AID-CNCR2820340425>3.0.CO;2-9","article-title":"Mullerian adenosarcoma of the uterus. A clinicopathologic analysis often cases of a distinctive type of mullerian mixed tumor","volume":"34","author":"Clement","year":"1974","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/gyno.2001.6334","article-title":"Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival","volume":"83","author":"Krivak","year":"2001","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(90)90198-E","article-title":"Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature","volume":"21","author":"Clement","year":"1990","journal-title":"Hum Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181cfe732","article-title":"Mullerian adenosarcoma of the female genital tract","volume":"17","author":"McCluggage","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.10.013","article-title":"Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study","volume":"143","author":"Seagle","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200210000-00001","article-title":"Mesodermal (mullerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature","volume":"26","author":"Eichhorn","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/path.4442","article-title":"Targeted genomic analysis of Mullerian adenosarcoma","volume":"235","author":"Howitt","year":"2015","journal-title":"J Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01160-1","article-title":"Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors","volume":"35","author":"Momeni Boroujeni","year":"2022","journal-title":"Mod Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000907","article-title":"High-grade mullerian adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior","volume":"41","author":"Hodgson","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN guidelines\u00ae insights: cervical cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"B13","doi-asserted-by":"publisher","first-page":"403431","DOI":"10.1155\/2015\/403431","article-title":"Advanced mesodermal (Mullerian) adenosarcoma of the ovary: metastases to the lungs, mouth, and brain","volume":"2015","author":"Daskalaki","year":"2015","journal-title":"Case Rep Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.10.022","article-title":"Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence","volume":"135","author":"Carroll","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00237","article-title":"Uterine adenosarcoma: A retrospective 12-year single-center study","volume":"9","author":"Yuan","year":"2019","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/2193-1801-2-618","article-title":"Therapeutic effect of dienogest on adenosarcoma arising from endometriosis: a case report","volume":"2","author":"Tasaka","year":"2013","journal-title":"Springerplus"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O'Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4209","DOI":"10.1038\/s41467-019-12032-9","article-title":"Recurrent GNAQ mutation encoding T96S in natural killer\/T cell lymphoma","volume":"10","author":"Li","year":"2019","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063284","article-title":"The GNAQ T96S mutation affects cell signaling and enhances the oncogenic properties of hepatocellular carcinoma","volume":"22","author":"Choi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c02002","article-title":"Discovery of darovasertib (NVP-LXS196), a pan-PKC inhibitor for the treatment of metastatic uveal melanoma","volume":"67","author":"Visser","year":"2024","journal-title":"J Med Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i14.1753","article-title":"Current status of the adjuvant therapy in uterine sarcoma: A literature review","volume":"7","author":"Rizzo","year":"2019","journal-title":"World J Clin cases"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4680273","article-title":"Treatment of recurrent or metastatic uterine adenosarcoma","volume":"2017","author":"Nathenson","year":"2017","journal-title":"Sarcoma"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1657939\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T05:20:28Z","timestamp":1764739228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1657939\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1657939"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1657939","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"article-number":"1657939"}}